The chief executive officer of Debiopharm's corporate subsidiary will be replaced by its acting chief strategy officer, Marc Cikes in early June
Tanja Dowe has announced her departure from Debiopharm Innovation Fund, the corporate fund of the Switzerland-based biopharmaceuticals corporation, Debiopharm. Tanja Dowe After serving more than five years as the fund’s chief executive officer, Dowe will be replaced by Marc Cikes who will continue to act as the unit’s chief strategy officer until June 1st. “I…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
